GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » OPKO Health Inc (XTAE:OPK) » Definitions » Institutional Ownership

OPKO Health (XTAE:OPK) Institutional Ownership : 13.94% (As of Apr. 30, 2025)


View and export this data going back to 2013. Start your Free Trial

What is OPKO Health Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, OPKO Health's institutional ownership is 13.94%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, OPKO Health's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, OPKO Health's Float Percentage Of Total Shares Outstanding is 58.67%.


OPKO Health Institutional Ownership Historical Data

The historical data trend for OPKO Health's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OPKO Health Institutional Ownership Chart

OPKO Health Historical Data

The historical data trend for OPKO Health can be seen below:

2024-06-30 2024-07-31 2024-08-31 2024-09-30 2024-10-31 2024-11-30 2024-12-31 2025-01-31 2025-02-28 2025-03-31
Institutional Ownership 14.18 14.09 14.06 13.46 13.35 15.44 14.49 14.32 14.30 13.94

OPKO Health Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


OPKO Health Business Description

Traded in Other Exchanges
Address
4400 Biscayne Boulevard, Miami, FL, USA, 33137
OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Its segments include pharmaceutical and diagnostics. The Pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. The Diagnostics segment consists of clinical and genomics laboratory operations through BioReference and point-of-care operations. It generates the majority of its revenue from the Diagnostics segment.